William G. Christen

William G. Christen

Auto-generated profile, based on publicly available information

William G. Christen

Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2009 in Archives of internal medicine (1960)
Verified
Journal Article
Closed access
WCWilliam G. Christen
William G. Christen
RGRobert J. Glynn
Robert J. Glynn
ECEmily Y. Chew
Emily Y. Chew
CAChristine M. Albert
Christine M. Albert
JMJoAnn E. Manson
JoAnn E. Manson
Observational epidemiologic studies indicate a direct association between homocysteine concentration in the blood and the risk of age-related macular degeneration (AMD), but randomized trial data to examine the effect of therapy to lower homocysteine levels in AMD are lacking. Our objective was to examine the incidence of AMD in a trial of combined folic acid, pyridoxine hydrochloride (vitamin B(6)), and cyanocobalamin (vitamin B(12)) therapy. We conducted a randomized, double-blind, placebo-controlled trial including 5442 female health care professionals 40 years or older with preexisting cardiovascular disease or 3 or more cardiovascular disease risk factors. A total of 5205 of these women did not have a diagnosis of AMD at baseline and were included in this analysis. Participants were randomly assigned to receive a combination of folic acid (2.5 mg/d), pyridoxine hydrochloride (50 mg/d), and cyanocobalamin (1 mg/d) or placebo. Our main outcome measures included total AMD, defined as a self-report documented by medical record evidence of an initial diagnosis after randomization, and visually significant AMD, defined as confirmed incident AMD with visual acuity of 20/30 or worse attributable to this condition. After an average of 7.3 years of treatment and follow-up, there were 55 cases of AMD in the combination treatment group and 82 in the placebo group (relative risk, 0.66; 95% confidence interval, 0.47-0.93 [P = .02]). For visually significant AMD, there were 26 cases in the combination treatment group and 44 in the placebo group (relative risk, 0.59; 95% confidence interval, 0.36-0.95 [P = .03]). These randomized trial data from a large cohort of women at high risk of cardiovascular disease indicate that daily supplementation with folic acid, pyridoxine, and cyanocobalamin may reduce the risk of AMD.

1 July 2011 in Archives of Ophthalmology (1950)
Verified
Journal Article
Open access
PDF file
WCWilliam G. Christen
William G. Christen
DSDebra A. Schaumberg
Debra A. Schaumberg
RGRobert J. Glynn
Robert J. Glynn
JBJulie E. Buring
Julie E. Buring
An estimated 9 million US adults aged 40 years and older show signs of age-related macular degeneration (AMD).1 Most cases of severe vision loss associated with the disease are due to advanced AMD, either central geographic atrophy or neovascular AMD, which affects an estimated 1.7 million persons.1 An additional 7.3 million persons have early AMD, which is usually associated with moderate or no vision loss2,3 but does increase the risk of progression to advanced AMD.4-6 Current treatment options are limited to a minority of persons with late-stage neovascular AMD7-12 or intermediate AMD.13 For the large majority of persons with early or no AMD, there is no recognized means of disease prevention other than avoiding cigarette smoking.14-16 Thus, the identification of means to prevent or delay the development of AMD would have marked public health significance.

1 January 2008 in Archives of Ophthalmology (1950)
Verified
Journal Article
Open access
PDF file
WCWilliam G. Christen
William G. Christen
SLSimin Liu
Simin Liu
RGRobert J. Glynn
Robert J. Glynn
JGJ. Michael Gaziano
J. Michael Gaziano
JBJulie E. Buring
Julie E. Buring
The oxidative hypothesis of cataract formation posits that reactive oxygen species can damage lens proteins and fiber cell membranes and that nutrients with antioxidant capabilities can protect against these changes.1-3 Results of laboratory studies and studies in animals generally support the antioxidant hypothesis, but results of observational epidemiologic studies in humans have been inconsistent.4-6Moreover, results of completed randomized trials7-14 indicate that supplemental use of vitamin E, ascorbic acid (vitamin C), or beta carotene for as long as 6.5 years (12 years for beta carotene7) has no marked effect on cataract incidence or progression. Whether a longer duration of treatment with these antioxidants can materially reduce the risk of cataract, which develops slowly across many years, remains to be determined in recently completed and ongoing trials.15-17

8 November 2010 in Archives of Ophthalmology (1950)
Verified
Journal Article
Closed access
PDF file
WCWilliam G. Christen
William G. Christen
RGRobert J. Glynn
Robert J. Glynn
HSHoward D. Sesso
Howard D. Sesso
TKTobias Kurth
Tobias Kurth
JMJean MacFadyen
Jean MacFadyen
JGJ. Michael Gaziano
J. Michael Gaziano
Objective To test whether supplementation with alternate-day vitamin E or daily vitamin C affects the incidence of age-related cataract in a large cohort of men. Methods In a randomized, double-masked, placebo-controlled trial, 11 545 apparently healthy US male physicians 50 years or older without a diagnosis of cataract at baseline were randomly assigned to receive 400 IU of vitamin E or placebo on alternate days and 500 mg of vitamin C or placebo daily. Main Outcome Measure Incident cataract responsible for a reduction in best-corrected visual acuity to 20/30 or worse based on self-report confirmed by medical record review. Application to Clinical Practice Long-term use of vitamin E and C supplements has no appreciable effect on cataract. Results After 8 years of treatment and follow-up, 1174 incident cataracts were confirmed. There were 579 cataracts in the vitamin E–treated group and 595 in the vitamin E placebo group (hazard ratio, 0.99; 95% confidence interval, 0.88-1.11). For vitamin C, there were 593 cataracts in the treated group and 581 in the placebo group (hazard ratio, 1.02; 95% confidence interval, 0.91-1.14). Conclusion Long-term alternate-day use of 400 IU of vitamin E and daily use of 500 mg of vitamin C had no notable beneficial or harmful effect on the risk of cataract. Trial Registration clinicaltrials.gov Identifier:NCT00270647

1 March 2003 in Archives of Ophthalmology (1950)
Verified
Journal Article
Open access
PDF file
WCWilliam G. Christen
William G. Christen
JMJoAnn E. Manson
JoAnn E. Manson
RGRobert J. Glynn
Robert J. Glynn
JGJ. Michael Gaziano
J. Michael Gaziano
RSRobert D. Sperduto
Robert D. Sperduto
CHCharles H. Hennekens
Charles H. Hennekens
OXIDATIVE PROCESSES are believed to be an important contributing factor in the development of age-related cataract, a leading cause of visual impairment in the United States.1,2 Thus, there is considerable interest in determining whether vitamins with antioxidant properties lower risks of cataract development and progression. Laboratory studies support this possibility by showing that supplementation with antioxidant vitamins and minerals prevents or delays cataract development in vitro and in animal models.3-7 Observational epidemiologic studies in humans provide further support by showing that persons with higher intakes of fruits and vegetables, or higher plasma levels of various antioxidant nutrients, tend to have lower risks of cataract. The data for individual nutrients, however, including vitamins C and E and the carotenoids, are inconsistent. More important, in these observational studies the amount of uncontrolled and uncontrollable confounding may be as large as the most plausible small to moderate effect sizes, so data from randomized trials are necessary.

1 February 2014 in Ophthalmology
Verified
Journal Article
Closed access
WCWilliam G. Christen
William G. Christen
RGRobert J. Glynn
Robert J. Glynn
JMJoAnn E. Manson
JoAnn E. Manson
JMJean MacFadyen
Jean MacFadyen
VBVadim Bubes
Vadim Bubes
JGJ. Michael Gaziano
J. Michael Gaziano